Biotechnology UK clinical-stage biotech PureTech Health today announced that Imbrium Therapeutics, a subsidiary of Purdue Pharma, has exercised a license option under the companies’ R&A collaboration agreement to develop PureTech’s LYT-503/IMB-150 (formerly designated as ALV-107), a non-opioid therapeutic candidate being developed for interstitial cystitis/bladder pain syndrome (IC/BPS). 11 August 2021